10-Q: Alkermes Reports Q1 2024 Results, Driven by Manufacturing and Royalty Revenue Growth

Alkermes reported a net income of $36.8 million for the first quarter of 2024, a significant turnaround from a net loss in the same period last year, primarily driven by increased manufacturing and royalty revenues.

Summary

• Alkermes reported a net income of $36.8 million for the first quarter of 2024, compared to a net loss of $41.8 million in the same period of 2023.
• The company's revenue increased to $350.4 million, up from $287.6 million in the first quarter of 2023.
• Manufacturing and royalty revenues saw a substantial increase, reaching $116.8 million, compared to $72.9 million in the prior year.
• Product sales, net, also increased to $233.5 million from $214.7 million year-over-year.
• Operating expenses decreased slightly to $307.1 million from $298.6 million.
• The company's cash and cash equivalents stood at $420.8 million as of March 31, 2024.
• The company completed the sale of its Athlone facility to Novo Nordisk on May 1, 2024.

Sentiment

Score: 8

Explanation: The document presents a strong positive sentiment due to the significant improvement in financial results, particularly the turnaround from a net loss to a net income. The increase in manufacturing and royalty revenues, along with the growth in LYBALVI sales, indicates positive momentum. However, the expected decrease in INVEGA SUSTENNA royalties and ongoing litigation introduce some caution.

Positives

• The company experienced a significant increase in manufacturing and royalty revenues, primarily due to the resolution of arbitration proceedings with Janssen.
• LYBALVI product sales saw a substantial increase of 56% year-over-year, indicating strong market uptake.
• The company's overall financial performance improved significantly, moving from a net loss to a net income.
• Alkermes maintains a strong cash position with $420.8 million in cash and cash equivalents.
• The sale of the Athlone facility was completed, which may streamline operations and reduce costs.

Negatives

• VIVITROL sales saw a slight increase in revenue but a decrease in unit sales.
• ARISTADA and ARISTADA INITIO sales were relatively flat, with a decrease in unit sales offsetting a price increase.
• The company's royalty revenues from INVEGA SUSTENNA are expected to end on August 20, 2024, which will likely impact future revenue.
• The company is involved in ongoing litigation related to INVEGA SUSTENNA and INVEGA TRINZA, which could impact future revenue.

Risks

• The company faces potential risks from competition, including generic versions of its products.
• The company is involved in ongoing litigation related to its products, which could have a material adverse effect on its business.
• The company's future royalty revenues from INVEGA SUSTENNA are expected to decrease significantly after August 20, 2024.
• The company's R&D programs are subject to risks and uncertainties, and the status, timing, and scope of these programs are subject to change.
• The company is exposed to non-U.S. currency exchange risk related to manufacturing and royalty revenues.

Future Outlook

The company expects royalty revenues from net sales of the long-acting INVEGA products to decrease in the near-term, as the royalty revenues related to net sales of INVEGA SUSTENNA are expected to end on August 20, 2024. The company also expects to initiate a phase 2 study in patients with narcolepsy type 2 in the second half of 2024.

Management Comments

• The company's net income from continuing operations was $38.9 million or $0.23 per ordinary share basic and diluted, for the three months ended March 31, 2024.
• The net income from continuing operations during the three months ended March 31, 2024, as compared to the net loss from continuing operations during the three months ended March 31, 2023, was primarily due to an increase of $44.0 million in manufacturing and royalty revenues, an increase of $18.8 million in product sales, net and a decrease of $7.7 million in amortization of acquired intangible assets, partially offset by an increase of $11.9 million in selling, general and administrative expense, and an increase of $6.4 million in R&D expense.

Industry Context

The results reflect a positive trend in the biopharmaceutical industry, where companies with strong product portfolios and strategic collaborations can achieve significant revenue growth. The increase in manufacturing and royalty revenues highlights the importance of licensing agreements and technology platforms in driving financial performance. The company's focus on neuroscience aligns with the growing demand for treatments in this therapeutic area.

Comparison to Industry Standards

• Alkermes' revenue growth in Q1 2024, particularly in manufacturing and royalty revenues, is notable compared to some of its peers in the biopharmaceutical industry.
• The company's performance in the neuroscience space is comparable to other companies focused on developing treatments for neurological disorders, such as Biogen, with whom they have a collaboration agreement for VUMERITY.
• The company's LYBALVI sales growth is a positive indicator of its commercial execution, which is a key factor in the success of pharmaceutical companies.
• The company's cash position is strong, which is important for funding ongoing R&D and commercialization activities, similar to other well-capitalized biopharmaceutical companies.
• The company's ongoing litigation related to INVEGA SUSTENNA and INVEGA TRINZA is a common risk faced by pharmaceutical companies with patent-protected products, similar to other companies facing generic competition.

Legal Proceedings

• The company is involved in litigation related to INVEGA SUSTENNA and INVEGA TRINZA.
• The company is involved in litigation related to VUMERITY.
• The company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL.
• The company is involved in product liability cases alleging that the FDA-approved VIVITROL labeling was inadequate and caused the users of the product to suffer from opioid overdose and death.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and the potential for future growth.
• Employees may benefit from the company's continued success and growth.
• Customers will benefit from the company's continued development and commercialization of innovative medicines.
• Suppliers may benefit from the company's continued operations and growth.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company expects to initiate a phase 2 study in patients with narcolepsy type 2 in the second half of 2024.
• The company will continue to monitor the impact of the end of INVEGA SUSTENNA royalties on its future revenue.
• The company will continue to defend itself in ongoing litigation related to its products.

Key Dates

Keywords

Alkermes, LYBALVI, VIVITROL, ARISTADA, Manufacturing Revenue, Royalty Revenue, Pharmaceuticals, Neuroscience, Financial Results, Q1 2024